DBV Technologies reported -18513000 in EBITDA for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
DBV Technologies DBVT:US -18513000 4.87M
Acadia Pharmaceuticals ACAD:US $ -33.14M 79.36M
Alnylam Pharmaceuticals ALNY:US $ -181.59M 44.32M
Amarin AMRN:US $ -36.84M 9.31M
Biomarin Pharmaceutical BMRN:US $ 64.42M 7.75M
Eleven Biotherapeutics EBIO:US $ -0.82M 9.8M
Esperion Therapeutics ESPR:US $ -52226000 9.39M
Halozyme Therapeutics HALO:US $ 46.61M 29.84M
Insmed INSM:US $ -98081000 92K
Intercept Pharmaceuticals ICPT:US $ -10.87M 0.98M
IONIS PHARMACEUT IONS:US $ -81.13M 27.92M
Neurocrine Biosciences NBIX:US $ 58.6M 52.2M
Ptc Therapeutics PTCT:US $ -63.18M 2.97M
Sarepta Therapeutics SRPT:US $ -201.24M 125.08M
Ultragenyx Pharmaceutical RARE:US $ -137.11M 4.57M
United Therapeutics UTHR:US $ 214.5M 86M
YTE INCY:US $ 276.8M 132.69M